Skip to content
Screener

AnaptysBio, Inc. ANAB Repurchase Of Common Stock Incurred But Not Yet Paid

Repurchase Of Common Stock Incurred But Not Yet Paid at other companies

Payoneer Global Inc. logo
Payoneer Global Inc.PAYO
$1.94M
Payoneer Global Inc. logo
Payoneer Global Inc.PAYO
$1.94M
Payoneer Global Inc. logo
Payoneer Global Inc.PAYO
$1.94M
Payoneer Global Inc. logo
Payoneer Global Inc.PAYO
$1.94M
Payoneer Global Inc. logo
Payoneer Global Inc.PAYO
$579.25K+199%
Payoneer Global Inc. logo
Payoneer Global Inc.PAYO
$579.25K+199%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.68B+200%
Enterprise value$1.43B+169%
P/S7.2×+2.7×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept anab:RepurchaseOfCommonStockIncurredButNotYetPaid.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026. Open the filing →

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515

FAQ

What is AnaptysBio, Inc.'s repurchase of common stock incurred but not yet paid?
AnaptysBio, Inc. (ANAB) reported repurchase of common stock incurred but not yet paid of $0 in Q1 2026.
How has AnaptysBio, Inc.'s repurchase of common stock incurred but not yet paid changed year-over-year?
AnaptysBio, Inc.'s repurchase of common stock incurred but not yet paid decreased by 100.0% year-over-year, from $959K to $0.
What does repurchase of common stock incurred but not yet paid mean?
This represents the value of common stock repurchases that have been committed to or authorized but for which the cash payment has not yet been settled. It serves as a liability indicator for capital return programs. Monitoring this helps investors understand the company's pending obligations regarding shareholder return initiatives.

Ask your AI about AnaptysBio, Inc.'s repurchase of common stock incurred but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude